Home Cart 0 Sign in  
X

[ CAS No. 39931-77-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 39931-77-6
Chemical Structure| 39931-77-6
Chemical Structure| 39931-77-6
Structure of 39931-77-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 39931-77-6 ]

Related Doc. of [ 39931-77-6 ]

Alternatived Products of [ 39931-77-6 ]

Product Details of [ 39931-77-6 ]

CAS No. :39931-77-6 MDL No. :MFCD00006411
Formula : C9H11NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :RPWXYCRIAGBAGY-UHFFFAOYSA-N
M.W : 165.19 Pubchem ID :96490
Synonyms :
Ethyl 3-pyridylacetate

Calculated chemistry of [ 39931-77-6 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.33
Num. rotatable bonds : 4
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.91
TPSA : 39.19 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.86 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.58
Log Po/w (XLOGP3) : 0.63
Log Po/w (WLOGP) : 1.19
Log Po/w (MLOGP) : 0.71
Log Po/w (SILICOS-IT) : 1.85
Consensus Log Po/w : 1.19

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.37
Solubility : 7.09 mg/ml ; 0.0429 mol/l
Class : Very soluble
Log S (Ali) : -1.03
Solubility : 15.5 mg/ml ; 0.0938 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.9
Solubility : 0.207 mg/ml ; 0.00125 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.7

Safety of [ 39931-77-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 39931-77-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 39931-77-6 ]
  • Downstream synthetic route of [ 39931-77-6 ]

[ 39931-77-6 ] Synthesis Path-Upstream   1~23

  • 1
  • [ 39931-77-6 ]
  • [ 3724-16-1 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 1988
  • 2
  • [ 39931-77-6 ]
  • [ 6293-56-7 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1992, vol. 29, # 6, p. 1663 - 1665
[2] Journal of Organic Chemistry, 2003, vol. 68, # 3, p. 718 - 725
[3] Patent: WO2012/75917, 2012, A1, . Location in patent: Page/Page column 36
  • 3
  • [ 39931-77-6 ]
  • [ 6443-85-2 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 1988
  • 4
  • [ 39931-77-6 ]
  • [ 501-81-5 ]
Reference: [1] Journal of the Chemical Society, 1958, p. 150,153
[2] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1981, vol. <B> 20, # 9, p. 793 - 795
[3] Patent: US6407120, 2002, B1, . Location in patent: Page column 23-24
  • 5
  • [ 39931-77-6 ]
  • [ 74-89-5 ]
  • [ 106271-65-2 ]
Reference: [1] Journal of the American Chemical Society, 1957, vol. 79, p. 2573,2577
  • 6
  • [ 626-55-1 ]
  • [ 6148-64-7 ]
  • [ 39931-77-6 ]
YieldReaction ConditionsOperation in experiment
87% With dmap; bis(η3-allyl-μ-chloropalladium(II)); 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl In 1,3,5-trimethyl-benzene at 140℃; for 20 h; Inert atmosphere General procedure: after standard cycles of evacuation and back-filling with dry and pure nitrogen, an oven-dried Schlenk tube equipped with a magnetic stirring bar was charged with Pd source (see Table 1, Table 2, Table 3 and Table 4), ligand (see Table 1, Table 2, Table 3 and Table 4), N,N-dimethylpyridin-4-amine (DMAP, see Table 1, Table 2, Table 3 and Table 4), and ethyl potassium malonate (see Table 1, Table 2, Table 3 and Table 4). The tube was evacuated and backfilled with argon (this procedure was repeated three times). Under a counter flow of argon, aryl halide (see Table 1, Table 2, Table 3 and Table 4) and solvent (see Table 1, Table 2, Table 3 and Table 4) were added by syringe. The tube was sealed and stirred at room temperature for 10 min. Then the tube was connected to the Schlenk line, which was full of argon, stirred in a preheated oil bath (140-150 °C) for the appointed time (20-25 h). Upon completion of the reaction, the mixture was cooled to room temperature and diluted with diethyl ether, and the yields were determined by gas chromatography using 1,3-dimethoxybenzene as the internal standard.
Reference: [1] Tetrahedron, 2012, vol. 68, # 9, p. 2113 - 2120
  • 7
  • [ 626-55-1 ]
  • [ 105-53-3 ]
  • [ 39931-77-6 ]
Reference: [1] Chemical Communications, 2001, # 24, p. 2704 - 2705
  • 8
  • [ 64-17-5 ]
  • [ 6419-36-9 ]
  • [ 39931-77-6 ]
YieldReaction ConditionsOperation in experiment
93% for 6 h; Reflux To a solution of 3-pyridylacetic acid hydrochloride (51) (12.00 g, 69.19 mmol) in EtOH (120 mL) was added concentrated H2SO4 (5 mL) and the solution was heated at reflux (6 h). The reaction mixture was concentrated in vacuo and diluted with EtOAc (200 mL). The EtOAc layer was washed with saturated aqueous NaHCO3 (3 x 200 mL) and brine (2 x 200 mL), and dried (Na2SO4). The crude product was purified by flash column chromatography (SiO2; 4:5 EtOAc/hexanes) to give the desired product (10.67 g, 93percent) as a pale yellow oil. Rf 0.37 (4:1 EtOAc/hexanes). 1H NMR (CDCl3) δ 1.26 (t, J = 7.2 Hz, CH2CH3), 3.63 (s, CH2C5H4N), 4.17 (q, J = 7.2 Hz, CH2CH3), 7.25-7.30 (m, C5H), 7.64-7.67 (m, C4H), 8.45-8.59 (m, C2H, C6H). 13C NMR (CDCl3) δ 13.7 (CH2CH3), 38.0 (CH2C5H4N), 60.7 (CH2CH3), 122.9 (C5H), 129.5 (C3H), 136.4 (C4H), 148.0 (C2H or C6H), 149.9 (C6H or C2).
Reference: [1] Synthetic Communications, 2012, vol. 42, # 8, p. 1137 - 1145
[2] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 11, p. 3551 - 3564
[3] Patent: WO2012/75917, 2012, A1, . Location in patent: Page/Page column 36
  • 9
  • [ 1120-90-7 ]
  • [ 6148-64-7 ]
  • [ 39931-77-6 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 2007, vol. 50, # 5-6, p. 277 - 280
  • 10
  • [ 626-60-8 ]
  • [ 6148-64-7 ]
  • [ 39931-77-6 ]
Reference: [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 19, p. 4470 - 4474
  • 11
  • [ 1120-90-7 ]
  • [ 141-97-9 ]
  • [ 39931-77-6 ]
Reference: [1] Chemical Communications, 2013, vol. 49, # 60, p. 6767 - 6769
  • 12
  • [ 100-55-0 ]
  • [ 95-92-1 ]
  • [ 39931-77-6 ]
Reference: [1] Chemistry - A European Journal, 2013, vol. 19, # 23, p. 7334 - 7337
  • 13
  • [ 1120-90-7 ]
  • [ 137344-20-8 ]
  • [ 39931-77-6 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 2007, vol. 50, # 5-6, p. 277 - 280
  • 14
  • [ 1120-90-7 ]
  • [ 5764-82-9 ]
  • [ 39931-77-6 ]
Reference: [1] Chemical & Pharmaceutical Bulletin, 1985, vol. 33, # 10, p. 4309 - 4313
[2] Journal of Labelled Compounds and Radiopharmaceuticals, 2007, vol. 50, # 5-6, p. 277 - 280
  • 15
  • [ 64-17-5 ]
  • [ 5423-64-3 ]
  • [ 39931-77-6 ]
Reference: [1] European Journal of Organic Chemistry, 2001, # 12, p. 2343 - 2361
  • 16
  • [ 100-55-0 ]
  • [ 39931-77-6 ]
Reference: [1] ChemMedChem, 2015, vol. 10, # 11, p. 1875 - 1883
  • 17
  • [ 6959-48-4 ]
  • [ 39931-77-6 ]
Reference: [1] ChemMedChem, 2015, vol. 10, # 11, p. 1875 - 1883
  • 18
  • [ 6443-85-2 ]
  • [ 64-17-5 ]
  • [ 39931-77-6 ]
Reference: [1] ChemMedChem, 2015, vol. 10, # 11, p. 1875 - 1883
  • 19
  • [ 350-03-8 ]
  • [ 39931-77-6 ]
Reference: [1] European Journal of Organic Chemistry, 2001, # 12, p. 2343 - 2361
  • 20
  • [ 50-00-0 ]
  • [ 89058-80-0 ]
  • [ 39931-77-6 ]
  • [ 89058-78-6 ]
Reference: [1] Tetrahedron, 1983, vol. 39, # 19, p. 3055 - 3058
  • 21
  • [ 3423-47-0 ]
  • [ 39931-77-6 ]
Reference: [1] Synthetic Communications, 2012, vol. 42, # 8, p. 1137 - 1145
  • 22
  • [ 39931-77-6 ]
  • [ 146667-84-7 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1992, vol. 29, # 6, p. 1663 - 1665
  • 23
  • [ 39931-77-6 ]
  • [ 197376-47-9 ]
Reference: [1] Synthesis, 1997, # 8, p. 949 - 952
[2] Synthesis, 1997, # 8, p. 949 - 952
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 39931-77-6 ]

Esters

Chemical Structure| 39998-25-9

[ 39998-25-9 ]

Methyl 2-(pyridin-3-yl)acetate

Similarity: 0.96

Chemical Structure| 1174229-72-1

[ 1174229-72-1 ]

Ethyl 2-(6-aminopyridin-3-yl)acetate

Similarity: 0.89

Chemical Structure| 54401-85-3

[ 54401-85-3 ]

Ethyl 4-pyridylacetate

Similarity: 0.89

Chemical Structure| 90610-06-3

[ 90610-06-3 ]

Methyl 2-(6-methylpyridin-3-yl)acetate

Similarity: 0.86

Chemical Structure| 29800-89-3

[ 29800-89-3 ]

Methyl 2-(pyridin-4-yl)acetate

Similarity: 0.85

Related Parent Nucleus of
[ 39931-77-6 ]

Pyridines

Chemical Structure| 39998-25-9

[ 39998-25-9 ]

Methyl 2-(pyridin-3-yl)acetate

Similarity: 0.96

Chemical Structure| 1174229-72-1

[ 1174229-72-1 ]

Ethyl 2-(6-aminopyridin-3-yl)acetate

Similarity: 0.89

Chemical Structure| 54401-85-3

[ 54401-85-3 ]

Ethyl 4-pyridylacetate

Similarity: 0.89

Chemical Structure| 90610-06-3

[ 90610-06-3 ]

Methyl 2-(6-methylpyridin-3-yl)acetate

Similarity: 0.86

Chemical Structure| 29800-89-3

[ 29800-89-3 ]

Methyl 2-(pyridin-4-yl)acetate

Similarity: 0.85